Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v2.4.0.8
Commitments and Contingencies - Additional Information (Detail) (USD $)
3 Months Ended 12 Months Ended
Mar. 31, 2014
Milestone
Dec. 31, 2012
UFRF License Agreements [Member]
   
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 5.00%  
Company's obligation to pay from all revenue received from sublicenses 22.00%  
One-time commercialization fee that would due on the first anniversary of first commercial sale $ 5,000  
Post-commercialization minimum royalty payments 50,000  
Minimum total cumulative royalties required to be paid for One-time additional royalty payment 2,000,000  
One-time additional payment to UFRF as a percentage of total royalties due to UFRF 10.00%  
Commercial sales 0  
Commercialization fees 0  
Minimum annual maintenance payment per license agreement 10,000  
Aggregate minimum annual maintenance payment 20,000  
Quarterly maintenance payment to UFRF under installment plan 5,000  
Termination notice period 90 days  
Texas A and M University License [Member]
   
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 5.00%  
Initial payment to Texas A&M 5,000  
Minimum consideration for the continuation of the license agreement 15,000  
Minimum annual amount to Texas A&M 100,000  
Annual maintenance payment under licensing agreement with Texas A&M 100,000  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2025  
Maintenance payment under licensing agreement with Texas A&M 400,000  
Maximum period to cure the breach 60 days  
Termination notice period 90 days  
Texas A and M University License [Member] | Phase I Clinical Trial [Member]
   
Commitment And Contingencies [Line Items]    
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2015  
Maintenance payment under licensing agreement with Texas A&M 50,000  
Texas A and M University License [Member] | Phase II Clinical Trial [Member]
   
Commitment And Contingencies [Line Items]    
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2019  
Maintenance payment under licensing agreement with Texas A&M 100,000  
Texas A and M University License [Member] | Phase III Clinical Trial [Member]
   
Commitment And Contingencies [Line Items]    
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2022  
Maintenance payment under licensing agreement with Texas A&M 150,000  
Texas A and M University License [Member] | Minimum [Member]
   
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 2.00%  
Probiotics ECC [Member]
   
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 10.00%  
Maximum period to cure the breach 60 days  
Termination notice period 90 days  
Milestone amount payable one 2,000,000  
Milestone measurement period 30 days  
Milestone amount payable two 5,000,000  
Milestone amount payable three $ 10,000,000  
Lantibiotic Exclusive Channel Collaboration (ECC) [Member]
   
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 25.00%  
Company's obligation to make payment from all revenue received from sublicensing 50.00%  
Number of shares issued   4,392,425
Maximum percentage of primary investment securities to investment of shares issued 10.00%  
Number of milestones achieved 0  
Termination notice period 90 days  
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Investigational New Drug Application [Member]
   
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 1.00%  
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Clinical Study Phase 2 [Member]
   
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 1.50%  
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Clinical Study Phase 3 [Member]
   
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 2.00%  
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Filing of First Investigational New Drug Application [Member]
   
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 2.50%  
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | First Regulatory Approval of Oragenics Product [Member]
   
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 3.00%